CKPT:NSD-Checkpoint Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.34

Change

+0.02 (+0.60)%

Market Cap

USD 0.23B

Volume

1.28M

Average Target Price

USD 16.00 (+379.04%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1 (PD-L1), which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was founded in 2014 and is headquartered in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Address: 2 Gansevoort Street, New York, NY, United States, 10014

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-10.59 (-6.73%)

USD62.28B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.68 (+0.80%)

USD54.69B 20.45 15.08
REGN Regeneron Pharmaceuticals, Inc

-8.19 (-1.77%)

USD49.61B 15.17 11.55
ALXN Alexion Pharmaceuticals, Inc

-1.60 (-1.05%)

USD33.27B 55.63 33.22
RPRX Royalty Pharma plc

-1.08 (-2.25%)

USD29.16B 22.60 14.17
BGNE BeiGene, Ltd

-12.93 (-4.05%)

USD29.03B N/A N/A
SGEN Seagen Inc

+1.16 (+0.76%)

USD27.64B 45.27 37.70
BNTX BioNTech SE

-5.23 (-4.75%)

USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.29 (-3.67%)

USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CKPT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 26.04% 66% D 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.04% 66% D 74% C
Trailing 12 Months  
Capital Gain 72.16% 68% D+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.16% 68% D+ 72% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -19.13% 16% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.13% 16% F 7% F
Risk Return Profile  
Volatility (Standard Deviation) 41.32% 68% D+ 35% F
Risk Adjusted Return -46.30% 18% F 13% F
Market Capitalization 0.23B 35% F 35% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.02 48% F 31% F
Price / Cash Flow Ratio -10.83 54% F 73% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -102.05% 28% F 11% F
Return on Invested Capital -162.14% 12% F 5% F
Return on Assets -48.07% 17% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.23 63% D 63% D
Short Percent 4.54% 58% F 40% F
Beta 1.73 34% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.